HC Wainwright Has Negative Estimate for TRVI FY2026 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at HC Wainwright cut their FY2026 EPS estimates for shares of Trevi Therapeutics in a report released on Wednesday, March 18th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.54) for the year, down from their previous estimate of ($0.50). HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at ($0.05) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04.

Several other equities analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Needham & Company LLC lifted their target price on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday. D. Boral Capital reiterated a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Morgan Stanley reduced their price target on shares of Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Stifel Nicolaus raised their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $21.60.

Trevi Therapeutics Trading Down 0.8%

Shares of NASDAQ TRVI opened at $10.61 on Friday. Trevi Therapeutics has a twelve month low of $4.85 and a twelve month high of $14.39. The stock has a fifty day simple moving average of $11.13 and a 200-day simple moving average of $10.95. The stock has a market capitalization of $1.36 billion, a PE ratio of -33.16 and a beta of 0.94.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after purchasing an additional 2,996 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Trevi Therapeutics in the fourth quarter valued at $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Trevi Therapeutics during the 4th quarter worth about $50,000. Strs Ohio purchased a new stake in Trevi Therapeutics during the 1st quarter worth about $52,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in shares of Trevi Therapeutics during the 2nd quarter worth about $56,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Key Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi beat Q4 2025 EPS expectations (reported -$0.06 vs. about -$0.096), providing near-term fundamental support and likely driving early buying interest after the print. Q4 2025 earnings transcript
• Positive Sentiment: Needham raised its price target to $24, signaling continued analyst conviction and a sizable implied upside from current levels. Needham raises PT to $24
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating, adding to the roster of buy-side endorsements that may support demand in the shares. D. Boral Capital reaffirms Buy
• Positive Sentiment: JonesTrading trimmed its price target slightly (from $25 to $24) but kept a Buy rating — the change is modest and leaves a large upside implied by street targets. JonesTrading PT update
• Neutral Sentiment: Full earnings-call transcript and coverage are available for investors reviewing management commentary and execution details; useful for gauging guidance and pipeline progress but not new news by itself. Earnings transcript
• Neutral Sentiment: Analyst write-ups (e.g., Globe and Mail summary) provide context and viewpoints but do not change fundamentals immediately. Analyst insights
• Negative Sentiment: HC Wainwright cut multi-year EPS forecasts across FY2026–FY2029 (notably downgrading several yearly EPS projections) while maintaining a Buy rating and a $21 target — the lower earnings trajectory may temper enthusiasm around near-term profitability and valuation. HC Wainwright estimate revisions
• Negative Sentiment: Morgan Stanley signaled lower expectations for TRVI, adding downward pressure from a major institutional voice and contributing to intraday weakness. Morgan Stanley lowers expectations

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.